Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3359609 plus pembrolizumab vs pembrolizumab plus placebo in first-line PD-L1 positive recurrent/metastatic head and neck squamous cell carcinoma
2019-002263-99Phase 2Completed
- Sponsor
- GSK
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing GSK3359609 + pembrolizumab with Pembrolizumab + placebo (2 arms). Primary endpoint: Overall survival. Started Dec 2019; status: completed.
02
Drugs
feladilimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2019-002263-99.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002263-99.